Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.81 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.81 |
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.81 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1724312 | 0.99 | KMT2A (0.81) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| SCHEMBL3717242 | 0.93 | CHRM1 (0.70) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL28927548 | 0.90 | CHRM1 (0.95) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL28927549 | 0.90 | CHRM1 (0.95) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL24175406 | 0.90 | CHRM1 (1.00) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL4966132 | 0.90 | CHRM1 (1.00) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL18603971 | 0.90 | CHRM1 (1.00) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL23371689 | 0.90 | CHRM1 (1.00) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL20754076 | 0.90 | CHRM1 (1.00) | CHRM1CHRM4CHRM2TSHRCHRM5 | |
| Scopolamine SCHEMBL22393238 | 0.90 | CHRM1 (1.00) | CHRM1CHRM4CHRM2TSHRCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956959-A | Methods and compositions for treating sleep apnea | 爱普宁公司(特拉华) | 2024-04-30 | — | — | CN | claimed |
| CN-117177741-A | Combination of norepinephrine reuptake inhibitors and cannabinoids for the treatment of sleep apnea | 爱普宁公司(特拉华) | 2023-12-05 | — | — | CN | claimed |
| CN-117062626-A | Methods and compositions for treating sleep apnea | 爱普宁公司(特拉华) | 2023-11-14 | — | — | CN | claimed |
| CN-116916909-A | Combination of reboxetine and a Muscarinic Receptor Antagonist (MRA) for the treatment of sleep apnea | 爱普宁公司(特拉华) | 2023-10-20 | — | — | CN | claimed |
| WO-2023196952-A2 | METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2022246405-A1 | METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH MUSCARINIC RECEPTOR ACTIVATION AND ANTIPSYCHOTICS | Karuna Therapeutics, Inc. (US) | 2022-11-24 | — | — | WO | claimed |
| US-20220175662-A1 | SUSTAINED RELEASE DEVICE FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER DISORDERS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-06-09 | — | — | US | claimed |
| CN-108014334-B | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or aversion to light in a subject in need thereof | H.伦德贝克公司 | 2021-11-30 | — | — | CN | claimed |
| US-20210236507-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING RELAPSE IN A PERSON WITH AN ADDICTION USING BETA ADRENERGIC RECEPTOR ANTAGONIST AND MUSCARINIC RECEPTOR ANTAGONIST COMBINATIONS | MAGNOLIA CNS, LLC | 2021-08-05 | — | — | US | claimed |
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| WO-2006017505-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING PLECONARIL FOR THE TREATMENT OF AIRWAY DISEASES | SCHERING CORPORATION (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060030550-A1 | Pharmaceutical formulations | SCHERING CORPORATION | 2006-02-09 | — | — | US | claimed |
| US-6890898-B2 | Inhibiting the dipeptidylpeptidase proteolysis of Glucagon-like peptide, by administering a dipeptides consisting Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala; treating metabolism disorders, diabetes, obesity, atherosclerosis | TRUSTEES OF TUFTS COLLEGE (US) | 2005-05-10 | — | — | US | claimed |
| EP-1520582-A2 | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism | TRUSTEES OF TUFTS COLLEGE (US) | 2005-04-06 | — | — | EP | claimed |
| US-5712265-A | ANTIDIABETIC AGENTS AND METABOIC AGGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1998-01-27 | — | — | US | claimed |
| EP-0764026-A4 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INC (US) | 1997-12-29 | — | — | EP | claimed |
| US-5700795-A | ADMINISTERING AT PREDETERMINED TIME TO DECREASE HYPERINSULINEMIA, HYPERGLYCEMIA, INSULIN RESISTANCE | THE GENERAL HOSPITAL CORPORATION (US) | 1997-12-23 | — | — | US | claimed |
| US-5668155-A | ALTERING LIPID METABOLISM IN VERTEBRATES FOR REDUCTION OF FATS | THE GENERAL HOSPITAL CORPORATION (US) | 1997-09-16 | — | — | US | claimed |
| EP-0764026-A1 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INCORPORATED (US) | 1997-03-26 | — | — | EP | claimed |
| WO-1995035110-A1 | ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS | ERGO SCIENCE INCORPORATED (US) | 1995-12-28 | — | — | WO | claimed |